Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Expenses (2016 - 2026)

Collegium Pharmaceutical has reported Operating Expenses over the past 10 years, most recently at $67.6 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 12.37% year-over-year to $67.6 million; the TTM value through Dec 2025 reached $283.6 million, up 36.72%, while the annual FY2025 figure was $283.6 million, 36.72% up from the prior year.
  • Operating Expenses for Q4 2025 was $67.6 million at Collegium Pharmaceutical, up from $67.1 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $75.6 million in Q1 2025 and troughed at $32.0 million in Q3 2021.
  • A 5-year average of $48.0 million and a median of $41.6 million in 2022 define the central range for Operating Expenses.
  • On a YoY basis, Operating Expenses climbed as much as 82.68% in 2024 and fell as far as 20.45% in 2024.
  • Year by year, Operating Expenses stood at $32.8 million in 2021, then increased by 15.99% to $38.0 million in 2022, then fell by 13.38% to $32.9 million in 2023, then skyrocketed by 82.68% to $60.2 million in 2024, then grew by 12.37% to $67.6 million in 2025.
  • Business Quant data shows Operating Expenses for COLL at $67.6 million in Q4 2025, $67.1 million in Q3 2025, and $73.3 million in Q2 2025.